Saturation is a core guiding principle to determine sample sizes in qualitative research, yet
little methodological research exists on parameters that influence saturation. Our study …

Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory
properties. This study evaluates the efficacy and safety of baricitinib in combination …

Background Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated
inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, …

Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in
studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a …

Durable control of human immunodeficiency virus (HIV) replication and lack of disease
progression in the absence of antiretroviral therapy were studied in a military cohort of 4586 …

Poor adherence to combined antiretroviral therapy (cART) has been shown to be a major
determinant of virologic failure, emergence of drug resistant virus, disease progression, …

Background Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through
wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir …

Background . Emergence of human immunodeficiency virus type 1 (HIV-1) drug resistance
may limit the benefits of antiretroviral therapy in resource-limited settings. The prevalence of …

Background Baricitinib and dexamethasone have randomised trials supporting their use for
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …

Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19).
In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, …